Kyowa Hakko’s IMMUSE, a clinically researched unique postbiotic, provides immune support in Lactoflor Immuno 200
Comple.med has added a new product to their lineup of food supplements and phytotherapeutics.
Lactoflor Immuno 200 is the first product to launch in Europe featuring IMMUSE. The formulation contains 50mg of IMMUSE, 200 mg of Lactoferin and 25 mcg of Vitamin D3.
Couple.med is an Italian based company engaged in the field of complementary medicines with an emphasis on phytotherapy.
IMMUSE Lactococcus lactis strain Plasma (LC-plasma), is a unique and patented postbiotic that proactively supports the immune system through a novel method of action that activates pDC (plasmacytoid dendritic cells). The pDC, a rare type of immune cell, has been shown to activate pivotal cells such as NK, Killer-T, Helper-T, and B cells, for a more comprehensive approach to immune support. It is this mechanism of action that differentiates IMMUSE from more conventional lactic acid bacteria or other immune ingredients.
“Immune health is a growing market sector in Europe, and we are so pleased to see our IMMUSE ingredient formulated into a Comple.med product, understanding the exacting standards they employed before bringing this innovative formulation to market,” commented Oksana Ritchie, Head of Marketing at Kyowa Hakko Europe.
We consider Kyowa Hakko to be a trusted partner who support all their ingredients with comprehensive and in-depth science
Before incorporating IMMUSE into Lactoflor Immuno 200, Comple.med undertook a rigorous process to ensure the highest standards and quality profiles consistent with the company’s pursuit of excellence. According to Eugenio Borghi, Comple.med director and research and development manager: “We consider Kyowa Hakko to be a trusted partner who support all their ingredients with comprehensive and in-depth science. That is very important to our company as we work to educate professionals in the health sector on the most appropriate and scientifically correct use of food supplements and phytotherapeutics.”
IMMUSE is backed by 29 published studies, including 14 human clinical trials, and over 10 years of research. It is marketed and sold by Kyowa Hakko, an international ingredients manufacturer whose primary goal is to provide health solutions that support optimal health for improved quality of life.